Navigation Links
The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene
Date:7/31/2014

estment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO


'/>"/>
SOURCE Zacks Investment Research, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
2. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
3. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
4. Zacks Bull and Bear of the Day Highlights: Smithfield Foods, Logitech International, Sanofi, Isis Pharmaceuticals and Aegerion Pharmaceuticals
5. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
6. Zacks Industry Outlook Highlights: Eli Lilly, Novo Nordisk, Biogen, Amgen and Osiris Therapeutics
7. Zacks Investment Ideas feature highlights: PharMerica, First Defiance Financial, American Railcar Industries and Big 5 Sporting Goods
8. Zacks.com featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
9. The Zacks Analyst Blog Highlights: Exxon Mobil, Statoil, Chevron, Braskem and Cubist Pharmaceuticals
10. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
11. The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... Calif. , Nov. 25, 2014 /PRNewswire/ ... company focused on the development of mobile ... accurate testing in hospital and pre-hospital settings, ... Organization (ISO) 13485:2003 certification.  The certification was ... one of the world,s leading certification bodies. ...
(Date:11/26/2014)... OAKS, Calif. and LONDON , ... ) and AstraZeneca (NYSE: AZN ) today announced ... evaluating two doses of brodalumab in more than 1,800 patients ... with both Stelara ® (ustekinumab) and placebo at week ... brodalumab weight-based analysis group were each shown to be superior ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... 5 ARKRAY, Inc., the world,s 5th largest manufacturer of ... clearance from the US Food and Drug Administration for its ... meter and strip platform, which ARKRAY will make available for ... complement to the existing GLUCOCARD line of products, and will ...
... 5 Cardiac Science Corporation (Nasdaq: ... ( AED ) and diagnostic cardiac monitoring devices, ... Jr., to its board of directors. Andrews replaces long-time board ... seat effective November 5th. The total number of directors remains ...
Cached Medicine Technology:ARKRAY, Inc. Receives FDA Clearance for New GLUCOCARD(R) Vital(TM) Blood Glucose Monitoring System 2Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 2Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 3Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 4Cardiac Science Appoints Healthcare Executive Ronald A. Andrews, Jr. to Board of Directors 5
(Date:11/26/2014)... (PRWEB) November 26, 2014 The ... Cardiology have launched a partnership designed to improve ... for congestive heart failure (CHF) patients in the ... staff and Lourdes Cardiology team will help CHF ... supervised protocols. This partnership pairs the Cardiac Recovery ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 Increasing ... stringent drug safety regulations are expected to be ... period. Growing prevalence of acute and chronic ailments ... for new drug development. Moreover, growing adverse drug ... the same has become the need of the ...
(Date:11/26/2014)... Raleigh, NC (PRWEB) November 26, 2014 ... types of materials science can cause mesothelioma that looks ... just posted a new article on the research. ... at the Fraunhofer Institute for Toxicology and Experimental Medicine ... nanotubes. While all of the rats eventually ...
(Date:11/26/2014)... The city of San Diego, California, because ... with a plan to recycle wastewater – also called ... supports the San Diego plan as part of her ... Kleyne, by recycling water that San Diego already owns, ... greatly reduced. (Spagat, E, “San Diego looks to sewers ...
(Date:11/26/2014)... 26, 2014 Loffler Companies has been ... in Imaging, an online information and news publication for ... the sixth consecutive year Loffler has earned this prestigious ... The Elite Dealer Awards honor the best and the ... Elite Dealer honorees were chosen for their innovative marketing ...
Breaking Medicine News(10 mins):Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 2Health News:Advanced Heart Failure Recovery Program comes to Deptford Center for Rehabilitation and Healthcare 3Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Pharmacovigilance Market To 2020 - Global Industry Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2
... By Amanda Gardner HealthDay Reporter , ... announced Thursday that they will lower the maximum amount ... products such as Vicodin and Percocet because of reports ... three years, the upper threshold of acetaminophen in prescription ...
... high blood pressure, according to new research by the University ... pressure or hypertension is one of the major ... and costs more than $300 billion each year. Around a ... 10 million people in the UK and one in three ...
... News) -- The more you walk, the lower your risk ... middle-aged adults who participated in a study to map diabetes ... health examination at the start of the study and provided ... were also given a pedometer and instructed how to use ...
... Randy Dotinga HealthDay Reporter , THURSDAY, Jan. ... severely obese women who suffer from incontinence, a new ... after undergoing gastric-band weight-loss surgery. "This could ... said Dr. Weranja K.B. Ranasinghe, the study,s lead author. ...
... Massachusetts General Hospital (MGH) Cancer Center researchers have discovered a ... of certain DNA sequences that do not code for proteins. ... been studied for their role in chromosomal structure but previously ... The report will appear in the journal Science ...
... News) -- Differences in income, gender and race influence ... a federal government report released Thursday shows. While ... healthy lives, disparities persist, according to the U.S. Centers ... people have five to 11 times fewer healthy days ...
Cached Medicine News:Health News:FDA Lowers Amount of Acetaminophen Allowed in Prescription Painkillers 2Health News:FDA Lowers Amount of Acetaminophen Allowed in Prescription Painkillers 3Health News:Bioactive compounds in berries can reduce high blood pressure 2Health News:The More You Walk, the Lower Your Diabetes Risk: Study 2Health News:Weight-Loss Surgery May Ease Incontinence in Women 2Health News:Weight-Loss Surgery May Ease Incontinence in Women 3Health News:Overexpression of repetitive DNA sequences discovered in common tumor cells 2Health News:Health Disparities Persist in U.S., Report Shows 2
The 570-90 is capable of producing up to 500 volts or 2,500 milliamps. It is an excellent choice for running all types of electroblotting applications. Also ideal for PAGE, SDS-PAGE, and DNA or RNA s...
... for horizontal and vertical gel electrophoresis applications. ... In this power supply model, output is ... constant voltage. Four sets of output terminals ... This power supply's light, compact and stackable ...
... The e-power series power ... any horizontal gel electrophoresis system. ... constructed to the most rigorous ... recognition as the most compact ...
... The PowerEase® 500 Power ... mini-gel electrophoresis. It offers extensive ... and four custom methods for ... own preferences. The simple, intuitive ...
Medicine Products: